使用 TPS 和 CPS 评估纳武利尤单抗治疗的头颈部癌的 PD-L1 表达与生存率。
PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer.
机构信息
Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan
出版信息
Anticancer Res. 2022 Mar;42(3):1547-1554. doi: 10.21873/anticanres.15628.
BACKGROUND/AIM: This study investigated the expression and survival rates of programmed cell death ligand 1 using the tumor proportion score (TPS)and combined positive score (CPS) for recurrent/metastatic head and neck cancer administered nivolumab.
PATIENTS AND METHODS
Forty-seven patients with recurrent/metastatic head and neck cancer with a history of platinum-based chemotherapy who received nivolumab between June 1st, 2017, and January 31st, 2019 were included in this study.
RESULTS
TPS and CPS were strongly correlated (r=0.546). When the TPS was high (≥40%), overall and progression-free survival were significantly better. The median overall survival was 8.5 months, median progression-free survival was not reached, and the 1-year progression-free survival rate was 71.4%. However, there was no significant difference in overall and progression-free survival between the groups with high CPS (≥20).
CONCLUSION
This is the first report to show a strong correlation between TPS and CPS. High TPS (40% or higher) may be used as a predictor of prognosis and efficacy. Further studies are warranted to determine the use of the CPS as a biomarker.
背景/目的：本研究旨在探讨程序性死亡配体 1 的表达和生存率，使用肿瘤比例评分（TPS）和联合阳性评分（CPS）来评估接受nivolumab 治疗的复发性/转移性头颈部癌症患者。
患者和方法
本研究纳入了 47 例接受nivolumab 治疗的复发性/转移性头颈部癌症患者，这些患者既往接受过铂类化疗。纳入时间为 2017 年 6 月 1 日至 2019 年 1 月 31 日。
结果
TPS 和 CPS 呈强相关性（r=0.546）。当 TPS 较高（≥40%）时，总生存期和无进展生存期显著改善。中位总生存期为 8.5 个月，中位无进展生存期未达到，1 年无进展生存率为 71.4%。然而，CPS 较高（≥20）的两组之间总生存期和无进展生存期无显著差异。
结论
这是首次报道 TPS 和 CPS 之间存在强相关性。高 TPS（40%或更高）可能可作为预后和疗效的预测指标。需要进一步的研究来确定 CPS 作为生物标志物的用途。
Zotero 插件